Dark

Check out our Level2View

CFBI
Community First Bancshares, Inc. Common Stock
stock NASDAQ

Inactive

Jan 20, 2021

11.12USD+9.940%(+1.01)39,039

Pre-market

0.00USD-100.000%(-10.11)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

07:07AM EST Can Fite Says First Patient Enrolled In Phase IIb NASH Clinical Trial With Namodenoson RTTNews

07:00AM EST Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson Business Wire

Jan 5, 2022

07:07AM EST Can-Fite BioPharma Expects Several Significant And Value-driving Events RTTNews

07:00AM EST Can-Fite Issues Letter to Shareholders Business Wire

Dec 20, 2021

04:05PM EST Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 GlobeNewswire Inc

07:13AM EST Liver Cancer Patient Treated With Can-Fite's Namodenoson Clears All Cancer Lesions Under Phase II Study; Stock Up RTTNews

07:00AM EST Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study Business Wire

Dec 7, 2021

07:05AM EST Can-Fite Says Phase 3 Psoriasis Study To Complete 16-Week Treatment Of Last Patient In January; Sees Topline Data In Q1 RTTNews

07:00AM EST Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022 Business Wire

Nov 26, 2021

07:06AM EST Can-Fite BioPharma 9-month Loss Per Share $0.02 Vs Loss $0.04 Last Year RTTNews

07:00AM EST Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update Business Wire

Nov 24, 2021

07:00AM EST Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021 Business Wire

Nov 12, 2021

07:00AM EST Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference Business Wire

Nov 1, 2021

07:00AM EDT Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting(r) 2021 Conference Business Wire

Oct 26, 2021

07:00AM EDT Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit Business Wire

Oct 21, 2021

12:12PM EDT Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal Benzinga

Oct 5, 2021

07:00AM EDT Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 Business Wire

Sep 22, 2021

07:00AM EDT Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021 Business Wire

Sep 17, 2021

07:00AM EDT Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences Business Wire

Sep 9, 2021

07:00AM EDT Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Sep 2, 2021

07:10AM EDT Can-Fite BioPharma Completes Patient Enrollment In Phase III Psoriasis Study RTTNews

07:00AM EDT Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study Business Wire

Aug 26, 2021

07:25AM EDT Can-Fite H1 Net Loss $5.09 Mln Vs Loss $8.23 Mln Last Year RTTNews

07:00AM EDT Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update Business Wire

Jul 8, 2021

07:00AM EDT Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study Business Wire

Jun 28, 2021

07:09AM EDT Can-Fite BioPharma Signs Agreement With Vetbiolix For Development Of Piclidenoson For Pets RTTNews

07:00AM EDT Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets Business Wire

Jun 2, 2021

07:00AM EDT Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021 Business Wire

May 27, 2021

06:00AM EDT Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report(r) Business Wire

May 6, 2021

07:00AM EDT Can-Fite to Present at Benzinga's Global Small Cap Conference on May 13, 2021 Business Wire

Apr 29, 2021

09:02AM EDT Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment RTTNews

07:00AM EDT Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021 Business Wire

Apr 5, 2021

07:00AM EDT Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies Business Wire

Mar 25, 2021

08:40AM EDT Can-Fite BioPharma 2020 Net Loss Widens To $14.44 Mln From $12.62 Mln Prior Year RTTNews

08:29AM EDT Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update Business Wire

Mar 19, 2021

07:00AM EDT Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report(r) Business Wire

Mar 16, 2021

07:04AM EDT Can-Fite BioPharma Signs $42.7 Mln Out-Licensing Deal With Ewopharma RTTNews

07:00AM EDT Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma Business Wire

Mar 5, 2021

07:08AM EST Can-Fite Enrolls First Of 40 Patients In Phase II COVID-19 Study Under FDA Protocol RTTNews

07:00AM EST Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol Business Wire

Feb 22, 2021

07:10AM EST New Positive Data from Can-Fite's Liver Cancer Phase II Clinical Study with Namodenoson Business Wire

Feb 1, 2021

07:25AM EST Can-Fite BioPharma Announces Inhibition Of Liver Fibrosis By Cannabis Compounds In Preclinical Studies RTTNews

07:00AM EST Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies Business Wire

Jan 28, 2021

07:01AM EST Can-Fite's NASH Indication Highlighted in Webinar by KOL Dr. Harrison: "Namodenoson May Have Big Impact on NASH" Business Wire

Jan 8, 2021

07:14AM EST Can-Fite Says Namodenoson Liver Cancer Study Published In Peer Reviewed Journal-Cancers RTTNews

07:00AM EST Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal-Cancers Business Wire

Dec 15, 2020

07:00AM EST Can-Fite Receives Israel Ministry of Health Approval to Conduct Research with Cannabinoids in Cancer, Inflammation and Obesity at the Company Discovery Labs Business Wire

Dec 14, 2020

07:05AM EST Can-Fite Says Currently Engaged In Design Of Phase IIb Study For Namodenoson In Treatment Of NASH RTTNews

07:00AM EST Can-Fite Reports on Progress With Its Namodenoson NASH Program Business Wire

Dec 3, 2020

07:00AM EST Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020 Business Wire

Nov 30, 2020

07:11AM EST Can-Fite BioPharma 9-month Net Loss $10.81 Mln Vs. Net Loss $7.84 Mln Last Year RTTNews

07:00AM EST Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update Business Wire

Nov 24, 2020

07:00AM EST Can-Fite's Namodenoson Abstract Selected as 'Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD) Business Wire

Nov 23, 2020

09:02AM EST Community First Bancshares Reports Commencement Of Stock Offering: Affinity Bancshares To Offer Up To 3.22M Shares, Subject To Increase To Up To 3.703M Shares Benzinga

07:00AM EST Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET Business Wire

Nov 16, 2020

07:00AM EST Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference Business Wire

Nov 9, 2020

07:00AM EST Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 Business Wire

Oct 13, 2020

07:00AM EDT Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 Business Wire

Oct 6, 2020

07:34AM EDT Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis RTTNews

Sep 30, 2020

07:00AM EDT Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson's Treatment of NASH at American Association for the Study of Liver Diseases Conference Business Wire

Sep 22, 2020

07:00AM EDT Can-Fite to Participate in Two BioPharma Partnering Conferences Business Wire

Sep 8, 2020

07:00AM EDT Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 Business Wire

Aug 31, 2020

07:00AM EDT FDA Clears Can-Fite to Commence Phase II COVID-19 Study Business Wire

Aug 27, 2020

07:05AM EDT Can-Fite 5-month Loss Per Share $0.04 Vs Loss $0.08 Last Year RTTNews

07:00AM EDT Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update Business Wire

Aug 25, 2020

08:14AM EDT Can-Fite Receives Notification Of Patent Grant From European Patent Office For Namodenoson In The Treatment Of NASH RTTNews

Aug 20, 2020

07:00AM EDT Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET Business Wire

Jul 27, 2020

07:14AM EDT Can-Fite Submits IND To FDA For COVID-19 Phase II Study Of Piclidenoson RTTNews

07:00AM EDT Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study Business Wire

Jul 20, 2020

07:00AM EDT Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds Business Wire

Jul 15, 2020

07:08AM EDT Can-Fite BioPharma Amends Phase II COVID-19 Study Protocol Based On Inputs From FDA RTTNews

07:00AM EDT Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly Business Wire

Share